Iovance Biotherapeutics, Inc. · NASDAQ:IOVA
Iovance Biotherapeutics — ESMO 2026
12 slides from Iovance Biotherapeutics's conference presentation, Oct 26, 2026
Slide 1: Lifileucel in Patients with Undifferentiated Pleomorphic Sarcoma (UPS) or Dedifferentiated Liposarcoma (DDLS)
Lifileucel in Patients with Undifferentiated Pleomorphic Sarcoma (UPS) or Dedifferentiated Liposarcoma (DDLS) Lauren Banks, MD, PhD Memorial Sloan Kettering Cancer Center New York, NY USA 26 October 2026
Slide 2: Declaration of Interests
Declaration of Interests 1. Principal Investigator (Site PI) for the investigator-initiated trial (IIT) [NCT05607095] on which this presentation is based. 2. Steering Committee Chair for the multicenter Phase II trial [IOV-SAR-201] that will be conducted based on data and findings from the aforement
Slide 3: UPS and DDLS: New therapies are needed
UPS and DDLS: New therapies are needed • Median OS for metastatic DDLS and UPS is <2 years (METASARC: Savina et al, BMC Med, 2017) • Median PFS after 1st line chemotherapy: 5-6 months (Tanaka et al, PLoS One, 2019; GeDDiS: Seddon et al, Lancet Oncol, 2017) Abbreviations: Leiomyosarcoma (LMS), Undiff
Slide 4: Lifileucel is an FDA approved TIL therapy in IO refractory melanoma
Lifileucel is an FDA approved TIL therapy in IO refractory melanoma ORR 31.4%; DOR at 5-year analysis 36.5 months Chesney et al. Journal for ImmunoTherapy of Cancer, 2022 Medina et al. Journal of Clinical Oncology, 2025 Content of this presentation is copyright and responsibility of the author. Perm
Slide 5: TILs are present in and can be expanded from STS
TILs are present in and can be expanded from STS Demico et al, Mod Pathol, 2019 Mullinax et al, Journal of Immunotherapy, 2021 Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
Slide 6: TIL harvest followed by infusion is feasible in STS
TIL harvest followed by infusion is feasible in STS Phase 1 study in AYA sarcoma • Primary endpoint = feasibility and safety • 5/7 patients had expanded TIL • No TIL-related toxicity – although LDC-related toxicity was seen • All patients with expanded product were infused Mullinax et al, CTOS, 2023
Slide 7: NCT05607095: Lifileucel pilot trial in DDLS/UPS
NCT05607095: Lifileucel pilot trial in DDLS/UPS 10 DDLS/UPS patients: • Candidate Identification • Unresectable/metastatic • Multidisciplinary discussion • ≥1 prior systemic therapy Screening • Screening studies per protocol • ≥1.5 cm lesion for TIL harvest • target lesion • Tumor harvest • +/- brid
Slide 8: Patient characteristics and cohort level outcomes
Patient characteristics and cohort level outcomes Characteristic N = 121 Characteristic N 95% CI Age at consent Primary Endpoints Median (Q1, Q3) 59 (49.5, 64) Feasibility1 10 (83.3%) 51.6%, 97.9% Mean (SD) 56.42 (8) AE incidence2 10 (100%) 69.2%, 100% Min, Max 43, 66 Secondary Endpoints2 Sex ORR (i
Slide 9: Patient-level data: Updated data cutoff
Patient-level data: Updated data cutoff Prior Prior Lifileucel Target IL-2 Best Age checkpoint DOR++ Sex Diagnosis treatment infusion SOD doses overall (y) inhibitor (weeks) lines (n) (Y/N) (mm) (n) response (Y/N) 66 M UPS 7 Y Y 114.7 2 PR 46 51 M DDLS 2 N Y 115.3 2 PR 26 43 F DDLS 2 N Y 39.0 5 PR 4
Slide 10: Tumor response
Tumor response Patient 1 (UPS) Patient 2 (DDLS) Patient 3 (DDLS) Baseline Follow up #4 (~6m post-TIL) Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
Slide 11: Conclusions and Highlights
Conclusions and Highlights • IIT led to design and opening of Phase II multicenter IOV-SAR-201 (SARATOGA study) • Many of the IIT patients would have qualified for SARATOGA Feasibility Safety Efficacy Future Directions • 10/12 patients • Expected grade 4 • ORR (in spec): 4/8 (50%, 2 • Analysis for e
Slide 12: Thank you!
Thank you! Patients and families Evan Rosenbaum, Sandra D’Angelo, Alexander Shoushtari, Edmund Bartlett MSK Sarcoma Oncology Service William Tap, Ciara Kelly, Ping Chi, Robert Maki, Sujana Movva, Damon Reed, Olayode Babatunde, Mary Keohan, Mark Dickson, Mrinal Gounder MSK Sarcoma/Thoracic Surgery Sa